Vertex Sinks 12% On Halt of VX-814 Development; Merrill Lynch Says Buy, , on October 15, 2020 at 8:12 am

By ILP
On 10/15/2020
In Financial News
Tags:

Shares in Vertex Pharmaceuticals plunged 12% in Wednesday’s extended market session after the pharma company announced the decision to stop the development of its VX-814 for the treatment in patients with alpha-1 antitrypsin deficiency (AATD), which is a genetic disorder increasing the risk for lung and liver disease.Vertex (VRTX) said that based on the safety and pharmacokinetic (PK) profile of VX-814 observed to date in a Phase 2 study, the company decided to halt trial dosing and will discontinue its development. Analysis of the PK data from the study indicated that exposures achieved were low and therefore Vertex concluded that it would not be feasible to safely reach targeted exposure levels. Vertex is considered the leader in the treatment of cystic fibrosis, a genetic disease that can severely affect lungs, pancreas and other organs.“Based on the liver enzyme elevations observed, along with the determination that we would not be able to safely achieve targeted exposure levels with VX-814, we are discontinuing further development of this molecule,” said Vertex Chief Medical Officer Carmen Bozic. “We are grateful to the AATD patients and investigators who participated in the VX-814 studies and we remain committed to transforming the treatment of this disease. We look forward to continuing clinical study of VX-864 and other molecules targeting the underlying cause of AATD.”The randomized, double-blind, placebo-controlled Phase 2 study of about 50 patients was designed to evaluate the safety and PK of VX-814, and the ability of VX-814 to increase functional levels of alpha-1 antitrypsin over 28 days of dosing. Elevated liver enzymes were observed in several patients. In 4 patients, across different doses studied, elevations greater than 8 times the upper limit of normal were noted.Vertex added that the company will continue to advance multiple small molecule correctors in late stage research with a goal of advancing at least one additional molecule into development in 2021.VRTX shares have already gained 24% this year with the $307.38 average analyst price target indicating 13% upside potential lies ahead. That’s with a cautiously optimistic Moderate Buy analyst consensus showing 11 Buys and 5 Holds.Merrill Lynch analyst Geoff Meacham reiterated a Buy rating on the stock with a $325 price target, calling the share move reaction “overdone”.“News that the VX-814 trial was stopped early due to safety concerns is certainly a blow to the strategy to diversify the pipeline outside of cystic fibrosis,” Meacham wrote in a note to investors.However, “Vertex’s strategy of bringing multiple products into the clinic simultaneously provides a hedge against unexpected safety issues such as this,” the analyst added. “We would consider the weakness a buying opportunity for Vertex shares given the strong base business and emerging pipeline.” (See VRTX stock analysis on TipRanks)Related News: PerkinElmer Raises 3Q Sales Outlook Fueled By COVID-19 Testing Demand J&J Halts Covid-19 Vaccine Trial Due To ‘Unexplained Illness’ Pfizer, BioNTech Initiate Rolling Canada Submission For Covid-19 Vaccine More recent articles from Smarter Analyst: * Organogenesis Soars 38% On Q3 Revenue, Boosts Guidance * Regeneron Scores FDA Nod For Ebola Treatment * BlackRock Invests $118M In EV Startup Arrival; Citi Sees 25% Upside * Taiwan Semiconductor 3Q Profit Up 45% Fueled By Chip Demand,

Vertex Sinks 12% On Halt of VX-814 Development; Merrill Lynch Says BuyShares in Vertex Pharmaceuticals plunged 12% in Wednesday’s extended market session after the pharma company announced the decision to stop the development of its VX-814 for the treatment in patients with alpha-1 antitrypsin deficiency (AATD), which is a genetic disorder increasing the risk for lung and liver disease.Vertex (VRTX) said that based on the safety and pharmacokinetic (PK) profile of VX-814 observed to date in a Phase 2 study, the company decided to halt trial dosing and will discontinue its development. Analysis of the PK data from the study indicated that exposures achieved were low and therefore Vertex concluded that it would not be feasible to safely reach targeted exposure levels. Vertex is considered the leader in the treatment of cystic fibrosis, a genetic disease that can severely affect lungs, pancreas and other organs.“Based on the liver enzyme elevations observed, along with the determination that we would not be able to safely achieve targeted exposure levels with VX-814, we are discontinuing further development of this molecule,” said Vertex Chief Medical Officer Carmen Bozic. “We are grateful to the AATD patients and investigators who participated in the VX-814 studies and we remain committed to transforming the treatment of this disease. We look forward to continuing clinical study of VX-864 and other molecules targeting the underlying cause of AATD.”The randomized, double-blind, placebo-controlled Phase 2 study of about 50 patients was designed to evaluate the safety and PK of VX-814, and the ability of VX-814 to increase functional levels of alpha-1 antitrypsin over 28 days of dosing. Elevated liver enzymes were observed in several patients. In 4 patients, across different doses studied, elevations greater than 8 times the upper limit of normal were noted.Vertex added that the company will continue to advance multiple small molecule correctors in late stage research with a goal of advancing at least one additional molecule into development in 2021.VRTX shares have already gained 24% this year with the $307.38 average analyst price target indicating 13% upside potential lies ahead. That’s with a cautiously optimistic Moderate Buy analyst consensus showing 11 Buys and 5 Holds.Merrill Lynch analyst Geoff Meacham reiterated a Buy rating on the stock with a $325 price target, calling the share move reaction “overdone”.“News that the VX-814 trial was stopped early due to safety concerns is certainly a blow to the strategy to diversify the pipeline outside of cystic fibrosis,” Meacham wrote in a note to investors.However, “Vertex’s strategy of bringing multiple products into the clinic simultaneously provides a hedge against unexpected safety issues such as this,” the analyst added. “We would consider the weakness a buying opportunity for Vertex shares given the strong base business and emerging pipeline.” (See VRTX stock analysis on TipRanks)Related News: PerkinElmer Raises 3Q Sales Outlook Fueled By COVID-19 Testing Demand J&J Halts Covid-19 Vaccine Trial Due To ‘Unexplained Illness’ Pfizer, BioNTech Initiate Rolling Canada Submission For Covid-19 Vaccine More recent articles from Smarter Analyst: * Organogenesis Soars 38% On Q3 Revenue, Boosts Guidance * Regeneron Scores FDA Nod For Ebola Treatment * BlackRock Invests $118M In EV Startup Arrival; Citi Sees 25% Upside * Taiwan Semiconductor 3Q Profit Up 45% Fueled By Chip Demand

,

Contact Us

Please use our Instant Quote form to see if you're pre-qualified for a non-recourse stock loan, or if you have any questions or feedback, please email, call or chat with us.

deals@internationalliquiditypartners.com

+44 20 3994 1588

Headquarters: Hunkins Waterfront Plaza, Charlestown, Nevis

Open 24 hours a day / 7 days a week / 365 days a year

 

 

 

Frequently Asked Questions

What Is Securities-Based Lending?
Securities-based lending, or a stock loan, is the practice of using market investments such as stocks, ETF’s, warrants, bonds, or real estate investment trusts as collateral for a loan.
How much money can I get for my securities?
Borrow up to 80% of the value of your pledged investments giving you the capital you need to expand your business, purchase real estate, or tackle a costly project.
What happens if my securities lose value?
With a non-recourse stock loan, you can walk away from your securities at any time and keep the loan money with no negative credit consequences even if the investments lose value.
Is my information safe with ILP?
We pride ourselves on outstanding service and make client confidentiality our top priority. You can always be absolutely certain your information is safe with us.
How long does it take for the disbursement of funds?
Most of the transactions we process take less than 7 days from application to the disbursement of funds giving you cash quickly when you need it most.
What credit score do I need to qualify?
There are no credit checks or personal guarantees necessary with our services. Your pledged securities are the only collateral required for the loan you receive.

Instant Quote

Please fill out your information to see if you are pre-qualified.

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

International Liquidity Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

International Liquidity Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with International Liquidity Partners, LLC’s internal lending policies. International Liquidity Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Nevis Office

Main Street
Hunkins Waterfront Plaza
Charlestown, Nevis

New York Office

Coming Soon!

Follow Us

Market Coverage